04/06/2010 - SPARK Ventures to realise its investment in Complinet  |  06/05/2010 - CNBC launches on Livestation  |  17/12/2009 - Livestation adds CNN International to its channel offering  |  IMImobile raises $13m of equity for expansion  |  18/09/2009 - Founders of SPARK Ventures’ portfolio company notonthehighstreet.com win ‘Entrepreneur of the Year'  |  28/08/2009 - SPARK Ventures realises its investment in Unanimis  |  19/06/2009 - Telecom Express and IMImobile join forces to launch IMEXmobile - Mobile Interaction Specialist

Biological therapies:

Celldex Therapeutics, Inc.

GlycArt AG

Glycoform

Haemostatix

Oxford BioMedica plc

Oxitec

Diagnostics & point-of-care:

IDG

Oxford Biosensors

Oxford Immunotec

Vivacta Limited

Disease Management & wellness:

Gemini Biomedical

Genosis plc

Instrumentation:

Teraview

IT in Healthcare:

Mirada Solutions

Medical Devices & Medical Technology:

(No investments to date)

Nanotechnology:

Oxonica plc

Pharmaceuticals and Speciality pharmaceuticals:

Allergy Therapeutics plc

Cyclacel Inc

Lectus Therapeutics

Medigene AG

Oxagen

PowerMed

Sterix

Vernalis plc

Xention

Telemedicine & e-Health:

(No investments to date)

 

PowderMed, an Oxford University spinout specialising in the emerging science of DNA-based vaccines, was sold to Pfizer, Inc., the world leading pharmaceutical company, in October 2006.

Quester invested in PowderMed in 2004. The offer from Pfizer, Inc. values PowderMed at circa £170 million, which represents a 5x return on Quester’s cost in less than 18 months.

PowderMed has developed a unique and proprietary technology which could potentially revolutionise the prevention and treatment of infectious diseases by delivering DNA directly to the cells of the body’s immune system. The company is also advancing a promising pipeline of proprietary vaccine candidates for influenza and chronic diseases.

View Website